GeoVax announced that it has been nominated in the Public Company category at the Buzz of BIO Contest, recognizing the Company as one of the most innovative companies at the upcoming 2019 CEO & Investor Conference sponsored by the Biotechnology Innovation Organization (BIO).

Please vote for GeoVax at  https://www.bio.org/events/bio-ceo-investor-conference/buzz-bio-voting. The voting window is short -- running from today (Dec 4) through Thursday (Dec 6) at 5:00pm so please vote at your earliest convenience. 

GeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please refer to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************